Posts

Tessa Therapeutics Hodgkin’s Lymphoma CAR-T therapy sho...

TT11X is an “off-the-shelf”, genetically modified cell therapy being trialed for...

ANeuroTech shares plans for major depressive disorder p...

The company plans to finish the round by September or October at the latest.

MSD’s Keytruda use in adenocarcinoma could be limited b...

This comes amongst various wins for Keytruda in recent years.

Race for universal flu vaccine ramps up as Osivax kicks...

The first patient has been dosed with Osivax’s broad-spectrum candidate in its P...

Avenge Bio secures FDA orphan drug designation for meso...

Pleural mesothelioma represents 85% of new mesothelioma cases, followed by perit...

Flamingo gets grant from VLAIO to accelerate RNA-focuse...

The grant comes after Flamingo announced a deal in March 2023 to merge its opera...

Testosterone supplementation not linked to heart attack...

Testosterone supplementation in men with low levels of the hormone did not incre...

STAT+: Trade group scolds drugmaker for ‘unethical’ att...

A U.K. trade group has rebuked Leo Pharma over an incident in which a company ma...

STAT+: Pharmalittle: FDA cites another troubled plant a...

The FDA discovered another troubled plant run by Intas Pharmaceuticals, a generi...

Getting rid of bias in clinical calculators isn’t as si...

Getting rid of bias in clinical calculators isn't as simple as taking race out o...

Why it won’t be so easy for medicine to displace BMI

“I think the trend is moving away from BMI, but these entrenched issues don’t fa...

Opinion: The DNA from dog tumors may hold the secret to...

Genomic data from the tumors of more than 4,000 dogs is offering insights for tr...

Opinion: The FDA needs a risk evaluation and mitigation...

The problem with the new Alzheimer’s drugs isn’t the drugs.

FDA advisers endorse updating Covid vaccines to target ...

On Thursday, the FDA's scientific advisers said the next round of Covid vaccines...

A chatbot that’s cautious about GPT, AI pronouncements,...

In the latest edition of STAT's Health Tech newsletter: a chatbot that's cautiou...

Listen: Biogen’s messy board, Laronde’s data problem, &...

Can unicorns survive without data? Did biotech get over its skis? And what is go...